Releases
16. October, 2024
Halfway milestone patient recruitment in Paediatric Study 0202
Cessatech announces that recruitment has today reached the halfway point for patient recruitment with...
Releases
26. August, 2024
Cessatech and Proveca announce world-wide excluding US commercial partnership for CT001
Cessatech and Proveca enter an exclusive agreement for the commercialization of CT001 world-wide excluding...
Releases
12. August, 2024
Cessatech extends Loan Facility Agreement to DKK 10 million…
Cessatech extends its undrawn Loan Facility Agreement to DKK 10 million to support the...
Releases
5. July, 2024
Anders Dyhr Dombernowsky-Toft appointed to the Board of Directors
Cessatech has today appointed Anders Dyhr Dombernowsky-Toft to the Board of Directors at the...
Releases
28. June, 2024
New data on paediatric pain relief at the PAGE conference in Rome favouring its lead candidate CT001
On 28 June – Cessatech A/S (“Cessatech” or “the Company”) announces that the presentation...
Releases
3. June, 2024
Cessatech announces superior simulated pain efficacy in children
Cessatech announces the final simulated efficacy data in children with CT001 from the abstract...
Releases
27. May, 2024
Cessatech reports first patient dosed in final Safety Study 0202 of lead product candidate CT001
Cessatech A/S announces that the Safety Study 0202 has now been initiated with dosing...
Releases
29. February, 2024
Annual Report 2023
Cessatech A/S publishes its annual report for the fiscal year 2023, which also includes...
Releases
9. January, 2024
Cessatech 2024 major milestones and focus
Now is the time – 2024 will be an extremely busy and hopefully exciting...
Releases
4. January, 2024
Q&A session – topline data from Study 0205
Link to release: (Link to Q&A session-image)
Releases
22. December, 2023
Positive topline data from study 0205 with its lead candidate CT001 for the treatment of pain in children supporting further advancement of CT001
The study a double-blinded, randomised, placebo-controlled in adults demonstrated that CT001 was superior to...
Releases
25. October, 2023
Cessatech announces that the Paediatric Committee has agreed to a 50% reduction of the required number of patients in the final study of its nasal spray for the treatment of acute pain in children
The European Paediatric Committee (PDCO) has agreed to a 50% reduction in the number...
Want to see all releases?
To see all releases including those not listed here, go to our filings and reports.